SS-31 Dosage Guide — Research Protocols | Real Peptides

SS-31 Dosage Guide — Research Protocols | Real Peptides

Research teams using SS-31 (elamipretide) face a deceptively simple problem: the same milligram-per-kilogram dose can produce wildly different mitochondrial outcomes depending on administration route, preparation method, and tissue target. A 3mg/kg subcutaneous injection delivers therapeutic concentrations to cardiac tissue within 90 minutes, while the same dose administered intravenously peaks in under 15 minutes but clears faster. The difference isn't academic. It determines whether your model shows measurable cardioprotection or not.

We've supplied SS-31 to research institutions across North America since 2018, and the most common dosing error isn't miscalculation. It's failing to match the route and schedule to the biological endpoint being measured. This SS-31 dosage guide covers the concentration ranges used in published research, how administration method alters pharmacokinetics, and what preparation mistakes compromise peptide stability before the first injection.

What is the standard SS-31 dosage range used in research models?

SS-31 dosage in preclinical research typically ranges from 0.05mg/kg to 10mg/kg depending on species, tissue target, and administration route. Rodent models commonly use 1-5mg/kg for cardioprotection studies and mitochondrial function assays, while higher doses (5-10mg/kg) appear in acute injury models such as ischemia-reperfusion. Subcutaneous administration permits once-daily or twice-daily dosing due to sustained plasma levels, whereas intravenous bolus requires more frequent administration to maintain therapeutic concentrations.

SS-31 Dosage Protocol Fundamentals

SS-31 (D-Arg-Dmt-Lys-Phe-NH2) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane through interaction with cardiolipin, a phospholipid essential to cristae structure and electron transport chain function. The mechanism of action is dose-dependent but not linear. Tissue concentrations above 2-3mg/kg in rodent models saturate cardiolipin binding sites, meaning further dose escalation doesn't proportionally increase mitochondrial benefit. This saturation threshold varies by tissue: cardiac muscle shows saturation around 3mg/kg, skeletal muscle around 5mg/kg, and renal tissue between 2-4mg/kg based on published biodistribution studies.

The half-life of SS-31 is approximately 3-4 hours in rodents following intravenous administration and 5-7 hours following subcutaneous injection due to depot formation and slower systemic absorption. This pharmacokinetic profile explains why most published protocols use twice-daily dosing for acute intervention studies and once-daily dosing for chronic treatment models extending beyond 14 days. Plasma concentration alone is a poor predictor of efficacy. Tissue penetration and mitochondrial accumulation lag behind peak plasma levels by 30-90 minutes depending on tissue perfusion.

Administration route fundamentally alters bioavailability and tissue distribution. Subcutaneous injection of SS-31 at 3mg/kg produces peak plasma concentrations of approximately 800-1200ng/mL within 60-90 minutes, with cardiac tissue levels reaching 200-400ng/g. Intravenous bolus at the same dose produces peak plasma concentrations exceeding 3000ng/mL within 5 minutes, but cardiac tissue levels plateau at similar concentrations (180-380ng/g) because mitochondrial uptake is rate-limited by cardiolipin availability, not plasma concentration. The practical implication: IV administration is preferred for acute protection models (e.g., ischemia-reperfusion within 2 hours), while subcutaneous is more appropriate for sustained mitochondrial support over days to weeks.

Reconstitution method directly impacts peptide stability and therefore effective dose. SS-31 Elamipretide supplied as lyophilized powder must be reconstituted with sterile saline or bacteriostatic water. Never DMSO, which can denature the peptide's tertiary structure. We recommend reconstitution to 5mg/mL concentration for rodent studies, which permits accurate micropipette measurement of doses in the 50-200μL range typical for subcutaneous injection in mice and rats. Once reconstituted, SS-31 remains stable at 2-8°C for up to 14 days; freeze-thaw cycles reduce potency by approximately 15-20% per cycle based on HPLC analysis of degradation products.

Route-Specific SS-31 Dosage Guidelines

Subcutaneous administration at 1-3mg/kg once daily is the most common protocol in published chronic heart failure, age-related mitochondrial dysfunction, and neurodegenerative disease models. This route produces steady-state plasma concentrations within 48-72 hours of the first dose, with trough levels sufficient to maintain mitochondrial membrane potential and reduce reactive oxygen species production. A representative protocol from a 2021 Circulation Research study used 3mg/kg subcutaneously once daily for 28 days in a rodent heart failure model, demonstrating 32% improvement in left ventricular ejection fraction compared to vehicle control. The subcutaneous route avoids the stress of repeated tail vein injections, reducing cortisol-mediated confounding in behavioral and metabolic endpoints.

Intravenous bolus at 2.5-5mg/kg is reserved for acute intervention studies where rapid mitochondrial protection is required. Ischemia-reperfusion injury, sepsis models, acute kidney injury, and stroke. A study published in Basic Research in Cardiology administered 5mg/kg IV 10 minutes before coronary artery occlusion, reducing infarct size by 43% compared to saline control. The same dose given 30 minutes after reperfusion showed only 18% reduction, illustrating the narrow therapeutic window for acute cardioprotection. IV administration requires precise timing and is incompatible with long-term studies due to technical difficulty and animal welfare considerations.

Intraperitoneal injection at 3-10mg/kg is used less frequently but offers a middle ground between subcutaneous and intravenous routes. Faster absorption than subcutaneous, less technical difficulty than IV. Bioavailability via IP is approximately 70-85% compared to IV, with peak plasma concentrations reached within 20-30 minutes. A mitochondrial myopathy study used 10mg/kg IP once daily for 21 days, showing restoration of ATP synthesis capacity in skeletal muscle without adverse effects. IP dosing is appropriate for pilot studies or when vascular access is technically prohibitive, but SC remains the preferred route for chronic dosing due to more predictable pharmacokinetics.

Oral administration is not viable for SS-31 due to peptide bond hydrolysis in the gastric and intestinal environment. Bioavailability is effectively zero. Any research protocol requiring enteral administration would necessitate encapsulation technology or chemical modification to protect the peptide backbone, which fundamentally alters the molecule and its mitochondrial targeting properties. Real Peptides supplies SS-31 exclusively for injectable research applications, consistent with the compound's established pharmacological profile.

Tissue-Specific SS-31 Dosage Optimization

Cardiac tissue demonstrates dose-dependent response between 0.5-3mg/kg, with maximal benefit observed at 2.5-3mg/kg in rodent models. A dose-response study in a doxorubicin-induced cardiomyopathy model showed that 1mg/kg reduced oxidative damage markers by 28%, 2.5mg/kg by 51%, and 5mg/kg by 53%. The plateau between 2.5mg/kg and 5mg/kg indicates saturation of cardiolipin binding sites. Cardiac mitochondria contain approximately 18% cardiolipin by phospholipid mass, the highest concentration of any tissue, which explains SS-31's preferential cardiac accumulation and the cardioprotective effects observed across multiple injury models.

Skeletal muscle requires higher doses (3-10mg/kg) to achieve comparable mitochondrial effects, likely due to lower cardiolipin content (approximately 10-12% of mitochondrial phospholipids) and greater tissue mass requiring distribution. A study in aged mice used 5mg/kg subcutaneously for 8 weeks, demonstrating 37% improvement in exercise endurance and 42% increase in mitochondrial respiration capacity measured via high-resolution respirometry. Skeletal muscle applications typically target age-related sarcopenia, mitochondrial myopathies, or metabolic dysfunction. Endpoints that require chronic dosing rather than acute intervention.

Renal tissue shows protection at 1-5mg/kg depending on injury model severity. A cisplatin-induced nephrotoxicity study used 2.5mg/kg subcutaneously starting 24 hours before cisplatin administration and continuing for 72 hours post-exposure, reducing serum creatinine elevation by 61% and tubular injury scores by 54%. Kidney mitochondria are particularly vulnerable to oxidative stress due to high metabolic demand and exposure to filtered toxins, making SS-31 an attractive research tool in acute kidney injury models. The relatively low effective dose reflects high renal perfusion and efficient mitochondrial uptake.

Neurological applications use 0.5-5mg/kg depending on the blood-brain barrier penetration required and the specific CNS region targeted. SS-31 crosses the blood-brain barrier, but penetration is limited. Brain tissue concentrations reach approximately 5-10% of plasma levels. A traumatic brain injury model used 5mg/kg IV immediately post-injury and again at 3 hours, reducing neuronal cell death by 39% and improving motor function recovery. Higher doses may be required for central nervous system endpoints compared to peripheral tissues, though doses above 10mg/kg have not demonstrated additional benefit and may introduce off-target effects.

SS-31 Dosage Guide: Administration Method Comparison

The table below compares dosage ranges, pharmacokinetic profiles, and research applications across the three viable administration routes for SS-31 in preclinical models.

Subcutaneous administration offers the best balance of efficacy, reproducibility, and animal welfare for the majority of research applications. Intravenous is indispensable for acute injury models but introduces technical variability and stress that can confound metabolic and behavioral endpoints. Intraperitoneal dosing is useful when SC absorption is too slow and IV access is impractical, though dose optimization may be required due to variable bioavailability.

Key Takeaways

• SS-31 dosage in rodent models typically ranges from 1-5mg/kg for chronic applications and 2.5-10mg/kg for acute injury models, with tissue-specific saturation occurring above 3-5mg/kg.
• Subcutaneous administration produces peak plasma concentrations in 60-90 minutes with a half-life of 5-7 hours, making it ideal for sustained mitochondrial support over days to weeks.
• Intravenous bolus delivers rapid mitochondrial protection within 10-15 minutes but requires precise timing and is limited to acute intervention studies.
• Cardiac tissue shows maximal benefit at 2.5-3mg/kg due to high cardiolipin content, while skeletal muscle and renal tissue require 3-10mg/kg and 1-5mg/kg respectively.
• Reconstitution with sterile saline or bacteriostatic water maintains SS-31 stability for 14 days at 2-8°C; freeze-thaw cycles reduce potency by 15-20% per cycle.
• Mitochondrial uptake is rate-limited by cardiolipin binding sites, not plasma concentration. Doses above tissue-specific saturation thresholds do not improve outcomes.

What If: SS-31 Dosage Scenarios

What If My Ischemia-Reperfusion Model Requires Dosing After the Injury Event?

Administer 5mg/kg IV within 30 minutes of reperfusion. Efficacy drops sharply after this window. Post-injury SS-31 administration in a coronary occlusion model reduced infarct size by 18% when given 30 minutes post-reperfusion but showed no significant benefit at 60 minutes, compared to 43% reduction with pre-ischemic dosing. The mitochondrial permeability transition pore (mPTP) opens within minutes of reperfusion, and SS-31's protective effect depends on stabilizing cardiolipin before mPTP-mediated cell death cascades become irreversible.

What If I Need to Extend My Study Duration Beyond 28 Days?

Continue 1-3mg/kg subcutaneous dosing once daily for up to 12 weeks without dose adjustment. Published chronic studies extending to 16 weeks in aging models showed no tolerance development or diminished response with continuous dosing. Monitor body weight and behavioral endpoints weekly. SS-31 does not alter food intake or body composition in healthy animals, so deviations suggest off-target effects or preparation issues. Mitochondrial benefits accumulate over time rather than plateau, with maximal improvement in respiratory capacity observed at 8-12 weeks in skeletal muscle aging studies.

What If Subcutaneous Administration Causes Injection Site Reactions?

Rotate injection sites across four anatomical locations (bilateral dorsal flanks, bilateral abdominal quadrants) and reduce injection volume to <200μL per site. Injection site irritation is rare with SS-31 but can occur if reconstitution pH is not neutral (6.5-7.5) or if injection volume exceeds tissue capacity. If irritation persists, consider splitting the daily dose into two smaller injections 12 hours apart rather than one bolus. Total daily dose remains unchanged but peak local concentration is reduced. Confirm reconstitution solution is sterile and free of particulates that could cause mechanical irritation.

What If My Model Requires Dosing in Larger Animals or Non-Human Primates?

Scale allometrically using body surface area (BSA) rather than direct mg/kg conversion. A 3mg/kg rodent dose converts to approximately 0.5-0.8mg/kg in primates. Primate studies published in JACC: Basic to Translational Science used 0.5mg/kg IV in a nonhuman primate heart failure model, showing similar cardioprotective effects to 3mg/kg in rodents. Larger animals have slower metabolic clearance and longer half-lives, requiring less frequent dosing. Once daily is typically sufficient compared to twice-daily in rodents. Pharmacokinetic pilot studies are essential before efficacy trials in large animal models.

The Evidence-Based Truth About SS-31 Dosage

Here's the honest answer: higher doses don't automatically produce better outcomes, and the belief that "more is better" leads to wasted compound and unreliable data. Once tissue cardiolipin binding sites saturate. Typically at 2.5-3mg/kg in cardiac tissue and 3-5mg/kg in skeletal muscle. Additional SS-31 remains in circulation without contributing to mitochondrial function. We've seen research teams escalate to 10-15mg/kg expecting proportional benefit, only to find identical endpoints to 3mg/kg while introducing unnecessary cost and potential off-target effects.

The real dosing decision is route and timing, not milligrams. A 2.5mg/kg IV dose administered 10 minutes before ischemia outperforms 10mg/kg given 60 minutes after reperfusion. Subcutaneous dosing at 2mg/kg twice daily beats 5mg/kg once daily in chronic models because sustained tissue levels matter more than peak plasma concentration. SS-31's therapeutic window is wide. Toxicity is not a concern at research doses. But efficacy is mechanism-limited, not dose-limited. Optimizing administration timing and frequency delivers better results than simply increasing the dose.

Another truth most dosing guides ignore: reconstitution and storage errors negate dosing precision entirely. A perfectly calculated 3mg/kg dose means nothing if the peptide degraded during reconstitution with the wrong diluent or underwent three freeze-thaw cycles. We conduct routine HPLC analysis on SS-31 Elamipretide returned by clients for potency verification, and degradation due to handling errors is more common than dosing calculation mistakes. Sterile technique, proper diluent selection, and single-use aliquoting eliminate this entirely preventable failure mode.

Finally, dose-response curves in mitochondrial research are rarely linear. SS-31 stabilizes cardiolipin, prevents cytochrome c release, and maintains cristae structure. These are threshold phenomena, not graded effects. A dose that achieves 50% receptor occupancy may produce 80% of maximal benefit, while doubling the dose to 100% occupancy adds only marginal improvement. This is why published studies plateau between 2.5-5mg/kg across multiple models and endpoints. Understanding the mechanism means you can design leaner, more reproducible protocols instead of empirically testing every dose increment from 1-10mg/kg.

SS-31 research requires precision in preparation, timing, and route selection. When institutions approach us for guidance on peptide protocols, we emphasize that effective dosing is about matching pharmacokinetics to biological endpoints. Not chasing the highest milligram-per-kilogram number in the literature. Start with published protocols in your specific model type, verify your reconstitution and storage procedures, and optimize timing before escalating dose.

What is SS-31 and how does it work?
SS-31 (elamipretide, also known as Bendavia or MTP-131) is a mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that selectively binds to cardiolipin, a phospholipid located in the inner mitochondrial membrane essential for cristae structure and electron transport chain function. By stabilizing cardiolipin, SS-31 prevents cytochrome c dissociation, reduces reactive oxygen species production, and maintains mitochondrial membrane potential during oxidative stress or ischemic injury. This mechanism makes SS-31 a valuable research tool in models of heart failure, ischemia-reperfusion injury, neurodegenerative disease, and age-related mitochondrial dysfunction.

How should SS-31 be reconstituted for injection?
Reconstitute lyophilized SS-31 with sterile saline (0.9% NaCl) or bacteriostatic water to a concentration of 5mg/mL for rodent studies, which permits accurate volumetric dosing in the 50-200μL range. Add diluent slowly down the vial wall rather than directly onto the lyophilized powder to minimize foaming and denaturation. Once reconstituted, gently swirl. Do not vortex. Until the powder fully dissolves. Store reconstituted solution at 2-8°C and use within 14 days. Never use DMSO, ethanol, or acidic buffers as diluents, as these denature the peptide backbone and eliminate mitochondrial targeting.

What is the difference between acute and chronic SS-31 dosing protocols?
Acute protocols (single dose to 7 days) typically use 2.5-10mg/kg intravenous or intraperitoneal administration to achieve rapid mitochondrial protection in injury models such as ischemia-reperfusion, sepsis, or acute kidney injury. Chronic protocols (7 days to 16 weeks) use 1-5mg/kg subcutaneous administration once or twice daily to provide sustained mitochondrial support in models of heart failure, aging, metabolic dysfunction, or neurodegeneration. Acute dosing prioritizes rapid tissue penetration and narrow therapeutic windows, while chronic dosing prioritizes steady-state plasma levels and minimal animal stress.

Can SS-31 dosage be scaled from rodents to larger animal models?
Yes, but use allometric scaling based on body surface area rather than direct mg/kg conversion. A 3mg/kg dose in mice (body surface area ~0.007 m²) converts to approximately 0.5-0.8mg/kg in primates (body surface area ~0.5-1.0 m²) using the formula: Dose_primate = Dose_mouse × (BSA_mouse / BSA_primate)^0.33. Larger animals have slower metabolic clearance and longer half-lives, so dosing frequency can often be reduced from twice daily in rodents to once daily in primates. Conduct pharmacokinetic pilot studies to confirm plasma concentrations and tissue distribution before starting efficacy trials.

What is the maximum safe dose of SS-31 in preclinical research?
Toxicity studies in rodents and primates have tested doses up to 30mg/kg without significant adverse effects, but doses above 5-10mg/kg do not improve efficacy due to saturation of cardiolipin binding sites. The therapeutic window is wide. The limiting factor is mechanism saturation, not toxicity. Most published research uses 1-5mg/kg for chronic studies and up to 10mg/kg for acute injury models. Doses above 10mg/kg are scientifically unnecessary and waste compound without improving outcomes.

How does administration route affect SS-31 tissue distribution?
Subcutaneous administration produces gradual absorption with peak plasma concentrations at 60-90 minutes and sustained tissue levels over 6-8 hours, making it ideal for chronic dosing. Intravenous bolus produces peak plasma concentrations within 5 minutes but clears faster, requiring precise timing for acute protection models. Intraperitoneal injection offers intermediate pharmacokinetics with peak levels at 20-30 minutes. Importantly, mitochondrial uptake is rate-limited by cardiolipin binding regardless of route. IV delivers compound faster but does not increase total mitochondrial accumulation compared to SC at equivalent doses.

Does SS-31 cross the blood-brain barrier?
Yes, but penetration is limited. Brain tissue concentrations reach approximately 5-10% of plasma levels. Despite limited CNS penetration, SS-31 has demonstrated neuroprotective effects in models of traumatic brain injury, stroke, and Alzheimer's disease, likely because even modest mitochondrial stabilization in neurons produces significant functional benefit. Neurological applications typically require higher doses (5-10mg/kg) compared to cardiac applications (2.5-3mg/kg) to compensate for lower brain bioavailability.

How long does reconstituted SS-31 remain stable?
Reconstituted SS-31 stored at 2-8°C maintains >95% potency for 14 days based on HPLC analysis. Freeze-thaw cycles cause approximately 15-20% potency loss per cycle due to peptide aggregation and bond hydrolysis. For studies requiring multiple dosing timepoints, prepare single-use aliquots immediately after reconstitution and freeze at −20°C or −80°C. Thaw each aliquot only once, immediately before use. Room temperature storage (20-25°C) reduces potency by approximately 10% per 24 hours and is not recommended beyond the time required for dose preparation.

What biological endpoints respond best to SS-31 treatment?
SS-31 demonstrates strongest effects on endpoints directly linked to mitochondrial function: ATP production capacity, mitochondrial membrane potential, reactive oxygen species levels, cytochrome c release, cristae structure (via electron microscopy), and respiratory control ratio measured by high-resolution respirometry. Secondary endpoints include infarct size in ischemia models, ejection fraction in heart failure models, exercise capacity in aging or myopathy models, and neuronal cell death in CNS injury models. Endpoints unrelated to mitochondrial dysfunction (e.g., inflammation driven by non-mitochondrial pathways) show variable or absent responses.

Are there published dose-response studies for SS-31?
Yes. A 2015 Cardiovascular Drugs and Therapy study tested 0.5, 1, 2.5, and 5mg/kg in a rodent doxorubicin cardiomyopathy model, showing dose-dependent reduction in oxidative damage up to 2.5mg/kg with plateau at 5mg/kg. A 2018 Aging study tested 1, 3, and 10mg/kg in aged mice, demonstrating maximal improvement in mitochondrial respiration at 3mg/kg with no additional benefit at 10mg/kg. These studies confirm that effective doses cluster in the 2.5-5mg/kg range for most applications, with higher doses providing no advantage once cardiolipin binding sites saturate.

Can SS-31 be combined with other mitochondrial-targeted compounds?
SS-31 has been combined with CoQ10, NAD+ precursors, and other mitochondrial therapeutics in published research without adverse interactions. However, redundant mechanisms (e.g., combining two cardiolipin-stabilizing peptides) do not produce additive benefit due to shared saturation limits. Synergistic approaches pair SS-31 with compounds targeting complementary pathways. For example, SS-31 for cristae stabilization plus NAD 100mg for SIRT1 activation. When designing combination studies, validate each compound's efficacy as monotherapy before testing combinations, and include appropriate vehicle controls for each agent.

Where can I source research-grade SS-31 for preclinical studies?
Research-grade SS-31 with verified purity and amino acid sequencing is available through specialized peptide suppliers such as Real Peptides, which provides small-batch synthesis with HPLC and mass spectrometry certificates of analysis. Verify that your supplier provides lyophilized powder rather than pre-reconstituted solution, as peptide stability is significantly higher in lyophilized form. Confirm purity exceeds 95% and that the supplier can provide documentation of synthesis method, storage conditions, and stability data. This traceability is essential for publication and regulatory compliance in preclinical research.

Most dosing errors aren't calculation mistakes. They're timing, route, and storage failures that happen before the syringe is filled. If tissue levels matter as much as plasma concentration, and cardiolipin saturation limits efficacy regardless of dose, the path to reproducible results is matching your protocol to the published pharmacokinetics rather than guessing at the highest tolerable dose.